RecruitingNCT02877706
French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia
Sponsor
University Hospital, Toulouse
Enrollment
1,500 participants
Start Date
Jun 1, 2013
Study Type
OBSERVATIONAL
Conditions
Summary
CARMEN is a national, real-world clinical registry of all adult patients with incident diagnosis of Immune thrombocytopenia (ITP) or Autoimmune Hemolytic anemia (AIHA) patients in France. It is aimed at describing ITP and AIHA clinical features, assessing the real-world risk-benefit ratio of treatments and adherence to guidelines for ITP and AIHA management.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- adult patients (18+ year-old)
- newly diagnosed for ITP/AIHA or initiation of FOSFAMATINIB
Exclusion Criteria1
- \- opposition to data collection
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERno specific intervention
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02877706
Related Trials
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
NCT0700796220 locations
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
NCT0710456540 locations
UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases
NCT074415251 location
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT072340191 location
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT072975631 location